Drug:
Reaction: INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION
20260101 - 20261231
No. 201 - 300
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 201 | 26930761 |
PH |
||
Cardiac arrest, Wrong technique in product usage process, Inappropriate schedule of product administration, Product prescribing issue, |
||||
TOLVAPTAN, |
||||
| 202 | 26930907 |
CA |
33 | 1 |
Dizziness, Infection, Nasal congestion, Pruritus, Throat clearing, Throat irritation, Inappropriate schedule of product administration, Off label use, |
||||
RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED, METHYLPREDNISOLONE, LEVOTHYROXINE SODIUM, |
||||
| 203 | 26930919 |
US |
2 | |
Neoplasm malignant, Muscle spasms, Diarrhoea, Inappropriate schedule of product administration, Constipation, Vomiting, |
||||
LINACLOTIDE, LINACLOTIDE, LINACLOTIDE, LINACLOTIDE, PANTOPRAZOLE, LENVATINIB, PEMBROLIZUMAB, |
||||
| 204 | 26921347 |
US |
19 | 1 |
Product use in unapproved indication, Inappropriate schedule of product administration, |
||||
BELUMOSUDIL, |
||||
| 205 | 26921422 |
US |
32 | 1 |
Multiple sclerosis relapse, Inappropriate schedule of product administration, |
||||
NATALIZUMAB, |
||||
| 206 | 26921444 |
CA |
54 | |
Colitis ulcerative, Symptom recurrence, Abdominal pain, Weight increased, Off label use, Inappropriate schedule of product administration, Wrong product administered, Suspected off label use, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, CALCIUM CARBONATE, ANTACID, ERGOCALCIFEROL, |
||||
| 207 | 26921510 |
US |
2 | |
Dermatitis atopic, Skin fissures, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 208 | 26921570 |
US |
1 | |
Inappropriate schedule of product administration, Illness, Nasopharyngitis, Malaise, |
||||
TIRZEPATIDE, TIRZEPATIDE, |
||||
| 209 | 26921583 |
CA |
77 | |
Knee operation, Hypertension, Weight decreased, Arthritis infective, White coat hypertension, Diarrhoea, Nasopharyngitis, Intentional dose omission, Off label use, Inappropriate schedule of product administration, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 210 | 26921631 |
US |
34 | |
Inappropriate schedule of product administration, Malaise, |
||||
TIRZEPATIDE, TIRZEPATIDE, |
||||
| 211 | 26921672 |
JP |
2 | |
Cataract, Rash, Injection site erythema, Injection site rash, Injection site pain, Injection site pruritus, Urticaria, Pruritus, Erythema, Inappropriate schedule of product administration, |
||||
INCLISIRAN, INCLISIRAN, |
||||
| 212 | 26921750 |
US |
2 | |
Inappropriate schedule of product administration, Product storage issue, |
||||
GUSELKUMAB, |
||||
| 213 | 26921754 |
CA |
25 | |
Haematochezia, Anorectal discomfort, Faeces discoloured, Defaecation urgency, Weight decreased, Influenza like illness, Arthralgia, Dyspepsia, Urinary tract infection, Intentional dose omission, Suspected off label use, Inappropriate schedule of product administration, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 214 | 26921907 |
US |
28 | 1 |
Ligament rupture, Pain, Eczema, Injection site pain, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 215 | 26921970 |
US |
59 | |
Inappropriate schedule of product administration, Incorrect dose administered, |
||||
MITOMYCIN, MITOMYCIN, MITOMYCIN, MITOMYCIN, MITOMYCIN, MITOMYCIN, |
||||
| 216 | 26922053 |
US |
2 | |
Diarrhoea, Inappropriate schedule of product administration, Intentional dose omission, |
||||
TROFINETIDE, |
||||
| 217 | 26922116 |
BR |
2 | |
Suicide attempt, Suicidal ideation, Asthenia, Pain, Feeling abnormal, Headache, Wound, Asphyxia, Neoplasm, Tumour pain, Apathy, Swelling, Renal impairment, Cardiac arrest, Eye disorder, Cardiac arrest, Coronavirus infection, Neoplasm malignant, Cardiomegaly, Pancreatic enlargement, Abnormal organ growth, Metastatic carcinoid tumour, Throat cancer, Metastasis, Metastasis, Disease recurrence, Metastases to bone, Diabetes mellitus, Bone pain, Bone marrow infiltration, Malaise, Cataract, Acromegaly, Lung disorder, Syncope, Pruritus, Pneumonia, Arrhythmia, Bone disorder, Visual impairment, Nervousness, Agitation, Feeding disorder, Mass, Panic reaction, Fear, Stress, Skin hypertrophy, Skin discolouration, Balance disorder, Hepatomegaly, Crying, Mood altered, Endocrine disorder, Deformity, Dyskinesia, Fall, Foot deformity, Dysphonia, Needle issue, Productive cough, Coating in mouth, Coating in mouth, Hormone level abnormal, Pancreatic disorder, Tongue disorder, Cardiac disorder, Gallbladder disorder, Liver disorder, Bacteroides test positive, Head injury, Malaise, Retching, Laziness, Skin discolouration, Malaise, Gait disturbance, Haemangioma of bone, Yellow skin, Cardiac valve disease, Gait disturbance, Decreased immune responsiveness, Sluggishness, General physical condition abnormal, Cyanosis, Neuralgia, Oropharyngeal pain, Dyspnoea, Pyrexia, Platelet count decreased, Vomiting, Muscular weakness, Decreased appetite, Headache, Asthenia, Headache, Insomnia, Influenza like illness, Anxiety, Dyspnoea, Fatigue, Back pain, Injection site pain, Therapeutic product effect delayed, Incorrect dose administered, Product quality issue, Product storage error, Inappropriate schedule of product administration, Product physical issue, |
||||
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, SERTRALINE, CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE, CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE, FLUOXETINE HYDROCHLORIDE, FLUOXETINE, |
||||
| 218 | 26922129 |
US |
||
Inappropriate schedule of product administration, Urinary tract infection, |
||||
MITOMYCIN, MITOMYCIN, |
||||
| 219 | 26922157 |
US |
64 | 2 |
Pneumonia, Inappropriate schedule of product administration, |
||||
BELUMOSUDIL, |
||||
| 220 | 26922364 |
US |
19 | 1 |
Inappropriate schedule of product administration, |
||||
SEBETRALSTAT, C1 ESTERASE INHIBITOR RECOMBINANT, |
||||
| 221 | 26922438 |
CA |
43 | 2 |
Rheumatoid factor positive, Pain, Peripheral swelling, Inappropriate schedule of product administration, Oedema, Musculoskeletal stiffness, Nasopharyngitis, Osteoarthritis, Rheumatic fever, Overdose, Paraesthesia, Obesity, Off label use, Muscular weakness, Sleep disorder, Peripheral venous disease, Rheumatoid arthritis, Night sweats, |
||||
CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, METHOTREXATE SODIUM, METHOTREXATE SODIUM, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, ALENDRONATE SODIUM, SECUKINUMAB, LEFLUNOMIDE, RITUXIMAB, RITUXIMAB, RITUXIMAB, METHOTREXATE SODIUM, METHOTREXATE SODIUM, METHOTREXATE SODIUM, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, |
||||
| 222 | 26922542 |
US |
||
Drug ineffective, Inappropriate schedule of product administration, |
||||
DICLOFENAC SODIUM, |
||||
| 223 | 26922734 |
US |
42 | 2 |
Myalgia, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 224 | 26922737 |
CA |
37 | |
Gallbladder operation, Weight decreased, Off label use, Inappropriate schedule of product administration, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 225 | 26922870 |
US |
55 | 2 |
Keratomileusis, Prescribed underdose, Inappropriate schedule of product administration, Product prescribing issue, Product use issue, |
||||
PERFLUOROHEXYLOCTANE, PERFLUOROHEXYLOCTANE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, |
||||
| 226 | 26923012 |
US |
54 | |
Inappropriate schedule of product administration, |
||||
NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, |
||||
| 227 | 26923027 |
US |
84 | |
Inappropriate schedule of product administration, Rash, |
||||
MITOMYCIN, MITOMYCIN, MITOMYCIN, |
||||
| 228 | 26923075 |
US |
11 | 2 |
Eczema, Pruritus, Dry skin, Skin discolouration, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 229 | 26923390 |
CA |
46 | |
Colitis ulcerative, Spinal pain, Musculoskeletal stiffness, Cough, Weight increased, Nasopharyngitis, Pain, Chills, Upper respiratory tract infection, Inappropriate schedule of product administration, Overdose, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB, ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, |
||||
| 230 | 26923424 |
US |
1 | |
Inappropriate schedule of product administration, |
||||
PIMAVANSERIN TARTRATE, PIMAVANSERIN TARTRATE, |
||||
| 231 | 26923450 |
EU |
69 | 2 |
Heritable pulmonary arterial hypertension, Platelet count decreased, Inappropriate schedule of product administration, |
||||
| 232 | 26923535 |
US |
72 | 1 |
Frequent bowel movements, Inappropriate schedule of product administration, |
||||
SODIUM SULFATE, POTASSIUM SULFATE, AND MAGNESIUM SULFATE, SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, SODIUM SULFATE, POTASSIUM SULFATE, MAGNESIUM SULFATE, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, SOTALOL HYDROCHLORIDE, FUROSEMIDE, CYCLOBENZAPRINE, LOSARTAN, DUTASTERIDE, MONTELUKAST, PANTOPRAZOLE, |
||||
| 233 | 26923578 |
US |
85 | 1 |
Inappropriate schedule of product administration, |
||||
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE ORAL, |
||||
| 234 | 26923603 |
US |
71 | 2 |
Condition aggravated, Inappropriate schedule of product administration, |
||||
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE ORAL, |
||||
| 235 | 26923643 |
US |
2 | |
Inappropriate schedule of product administration, |
||||
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE ORAL, LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE ORAL, |
||||
| 236 | 26923920 |
IN |
55 | 2 |
Mucosal inflammation, Bicytopenia, Drug clearance decreased, Accidental overdose, Inappropriate schedule of product administration, Toxicity to various agents, Product dispensing error, Product packaging confusion, Drug interaction, Vomiting, |
||||
METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, RABEPRAZOLE, PANTOPRAZOLE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, LEFLUNOMIDE, FOLIC ACID, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, DULOXETINE HYDROCHLORIDE, DULOXETINE, |
||||
| 237 | 26923982 |
CH |
1 | |
Malaise, Blood pressure increased, Vertigo, Dyspnoea at rest, Asthenia, Fatigue, Nasal congestion, Feeling hot, Dizziness, Heart rate increased, Inappropriate schedule of product administration, |
||||
SILDENAFIL CITRATE, SILDENAFIL, SILDENAFIL POWDER,, SILDENAFIL CITRATE, SILDENAFIL, TADALAFIL, TADALAFIL, ESOMEPRAZOLE MAGNESIUM, VALSARTAN, VALSARTAN ORAL, EZETIMIBE, |
||||
| 238 | 26924010 |
US |
63 | 2 |
Constipation, Bowel movement irregularity, Inappropriate schedule of product administration, |
||||
| 239 | 26924045 |
US |
||
Inflammation, Inappropriate schedule of product administration, |
||||
MITOMYCIN, MITOMYCIN, MITOMYCIN, MITOMYCIN, |
||||
| 240 | 26924047 |
US |
92 | |
Inappropriate schedule of product administration, |
||||
MITOMYCIN, MITOMYCIN, MITOMYCIN, MITOMYCIN, MITOMYCIN, |
||||
| 241 | 26924187 |
US |
1 | |
Appetite disorder, Back injury, Inappropriate schedule of product administration, |
||||
| 242 | 26924295 |
US |
44 | 1 |
Visual impairment, Inappropriate schedule of product administration, |
||||
INSULIN GLARGINE, INSULIN GLARGINE, |
||||
| 243 | 26924344 |
2 | ||
Muscle discomfort, Injection site rash, Injection site swelling, Inappropriate schedule of product administration, |
||||
| 244 | 26924397 |
CA |
47 | |
Colitis ulcerative, Haematochezia, Rash, Inappropriate schedule of product administration, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB, AZATHIOPRINE, LEVOTHYROXINE SODIUM, |
||||
| 245 | 26924670 |
US |
1 | |
Dandruff, Incorrect dose administered, Inappropriate schedule of product administration, |
||||
BIMEKIZUMAB, |
||||
| 246 | 26924776 |
US |
2 | |
Off label use, Behaviour disorder, Anger, Seizure, Drug ineffective, Somnolence, Mood altered, Inappropriate schedule of product administration, |
||||
STIRIPENTOL, STIRIPENTOL, STIRIPENTOL, STIRIPENTOL, STIRIPENTOL, CLONAZEPAM, ZONISAMIDE, CLONIDINE, IRON, |
||||
| 247 | 26924936 |
US |
79 | 2 |
Injection site warmth, Injection site mass, Injection site swelling, Injection site erythema, Injection site pruritus, Inappropriate schedule of product administration, |
||||
DUPILUMAB, ALBUTEROL SULFATE AND BUDESONIDE, AMLODIPINE BESYLATE, FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, ESCITALOPRAM OXALATE, ESCITALOPRAM, GABAPENTIN, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, TIZANIDINE HYDROCHLORIDE, ERGOCALCIFEROL, BUPROPION HYDROCHLORIDE, |
||||
| 248 | 26924945 |
US |
3 | 2 |
Dry skin, Pruritus, Product dose omission issue, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 249 | 26925044 |
US |
1 | |
Muscle rigidity, Musculoskeletal stiffness, Inappropriate schedule of product administration, |
||||
RISPERIDONE, |
||||
| 250 | 26925048 |
BR |
48 | 1 |
Large intestinal stenosis, Chronic gastritis, Haemorrhoids, Gastrooesophageal reflux disease, Haemorrhage, Inappropriate schedule of product administration, |
||||
INFLIXIMAB, INFLIXIMAB, |
||||
| 251 | 26925071 |
US |
36 | 2 |
Maternal exposure during pregnancy, Inappropriate schedule of product administration, |
||||
CERTOLIZUMAB PEGOL, |
||||
| 252 | 26925117 |
AU |
2 | |
Multiple sclerosis, Kidney infection, Urinary tract infection, Migraine, Candida infection, Inappropriate schedule of product administration, Sinusitis, Joint dislocation, Ear infection, |
||||
OFATUMUMAB, OFATUMUMAB, OFATUMUMAB, |
||||
| 253 | 26925236 |
US |
||
Drug ineffective, Inappropriate schedule of product administration, |
||||
DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, |
||||
| 254 | 26925239 |
US |
2 | |
Drug effect less than expected, Incorrect product administration duration, Inappropriate schedule of product administration, |
||||
DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, |
||||
| 255 | 26925242 |
US |
75 | |
Drug ineffective, Underdose, Wrong technique in product usage process, Inappropriate schedule of product administration, Incorrect product administration duration, |
||||
DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, |
||||
| 256 | 26925297 |
US |
2 | |
Drug ineffective, Wrong technique in product usage process, Underdose, Inappropriate schedule of product administration, Expired product administered, |
||||
DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, |
||||
| 257 | 26925300 |
US |
1 | |
Wrong technique in product usage process, Intentional product use issue, Drug ineffective, Incorrect product administration duration, Inappropriate schedule of product administration, Product administered at inappropriate site, |
||||
DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, FISH OIL, PREDNISONE, METHOTREXATE, METHOTREXATE SODIUM, ROSUVASTATIN, ASCORBIC ACID, |
||||
| 258 | 26925353 |
US |
67 | 2 |
Drug ineffective, Underdose, Inappropriate schedule of product administration, |
||||
DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, |
||||
| 259 | 26925362 |
US |
68 | 1 |
Therapeutic product effect variable, Inappropriate schedule of product administration, |
||||
DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, RIVAROXABAN, |
||||
| 260 | 26925384 |
US |
70 | 2 |
Drug ineffective, Inappropriate schedule of product administration, Incorrect product administration duration, Underdose, Wrong technique in product usage process, |
||||
DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, |
||||
| 261 | 26925391 |
US |
69 | 1 |
Drug ineffective, Inappropriate schedule of product administration, Pruritus, Rash, |
||||
DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, FAMOTIDINE, |
||||
| 262 | 26925568 |
CN |
61 | 1 |
Eosinophilic granulomatosis with polyangiitis, Infection, Condition aggravated, Temperature intolerance, Chills, Cough, Pyrexia, Back pain, Neutrophil percentage abnormal, Chromaturia, Inappropriate schedule of product administration, |
||||
MEPOLIZUMAB, |
||||
| 263 | 26925698 |
US |
51 | 2 |
Needle issue, Product use issue, Cough, Inappropriate schedule of product administration, |
||||
TEZEPELUMAB-EKKO, TEZEPELUMAB-EKKO, |
||||
| 264 | 26925936 |
US |
1 | |
Inappropriate schedule of product administration, |
||||
BIMEKIZUMAB, |
||||
| 265 | 26926048 |
US |
84 | 1 |
Blood glucose increased, Inappropriate schedule of product administration, |
||||
INSULIN GLARGINE, |
||||
| 266 | 26926208 |
US |
82 | 2 |
Confusional state, Nausea, Inappropriate schedule of product administration, Fatigue, |
||||
| 267 | 26926225 |
US |
46 | 1 |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 268 | 26926239 |
TH |
83 | 2 |
Death, Inappropriate schedule of product administration, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 269 | 26926248 |
US |
2 | |
Constipation, Inappropriate schedule of product administration, Nausea, Diarrhoea, |
||||
| 270 | 26926302 |
2 | ||
Joint dislocation, Dizziness, Inappropriate schedule of product administration, |
||||
REPOSITORY CORTICOTROPIN, |
||||
| 271 | 26926356 |
CA |
61 | |
Gastrointestinal obstruction, Abdominal operation, Harvey-Bradshaw index increased, Inappropriate schedule of product administration, Dizziness, Product dose omission issue, Off label use, Refusal of treatment by patient, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, PREDNISONE, |
||||
| 272 | 26926406 |
BR |
63 | 2 |
Oral contusion, Dry mouth, Dry skin, Skin exfoliation, Inappropriate schedule of product administration, Ageusia, Impaired quality of life, |
||||
TALQUETAMAB, |
||||
| 273 | 26926435 |
CA |
62 | |
Crohn^s disease, Skin cancer, Neurodermatitis, Off label use, Inappropriate schedule of product administration, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, AMLODIPINE BESYLATE, ESOMEPRAZOLE MAGNESIUM, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, DUPILUMAB, |
||||
| 274 | 26926514 |
CA |
67 | |
Ligament sprain, Off label use, Inappropriate schedule of product administration, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 275 | 26914818 |
US |
2 | 2 |
Meningitis viral, Catheter site infection, Inappropriate schedule of product administration, |
||||
ALGLUCOSIDASE ALFA, |
||||
| 276 | 26914821 |
US |
2 | |
Inappropriate schedule of product administration, |
||||
INSULIN GLARGINE, |
||||
| 277 | 26914880 |
US |
79 | 2 |
Fatigue, Malaise, Brain fog, Drug intolerance, Inappropriate schedule of product administration, |
||||
CLOPIDOGREL, CLOPIDOGREL BISULFATE, |
||||
| 278 | 26915037 |
US |
2 | |
Rash, Skin plaque, Miliaria, Inappropriate schedule of product administration, Dry skin, Back pain, Intervertebral disc protrusion, Coccydynia, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, AMITRIPTYLINE HYDROCHLORIDE, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, DULOXETINE HYDROCHLORIDE, DULOXETINE, DULOXETINE HYDROCHLORIDE, DULOXETINE, TIRZEPATIDE, NAPROXEN, NAPROXEN SODIUM, RIZATRIPTAN, SODIUM FLUORIDE, SODIUM FLUORIDE F 18, SODIUM FLUORIDE F-18, SODIUM FLUORIDE F18, CLEAR MINT, GEL TOOTHPASTE, TIZANIDINE HYDROCHLORIDE, INSULIN GLARGINE, |
||||
| 279 | 26915139 |
CA |
57 | |
Eyelid ptosis, Inappropriate schedule of product administration, Underdose, Suspected off label use, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 280 | 26915218 |
EU |
||
Glomerular filtration rate decreased, Cardiac failure congestive, Aortic valve incompetence, Blood creatinine increased, Inappropriate schedule of product administration, Contraindicated product administered, Off label use, Blood cholesterol abnormal, Weight increased, Heart rate increased, Oedema peripheral, Diarrhoea, |
||||
RIVAROXABAN, APIXABAN, EPLERENONE, EPLERENONE, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, PANTOPRAZOLE, TORSEMIDE, TORSEMIDE, TORSEMIDE, TORSEMIDE, VALSARTAN, VALSARTAN ORAL, WARFARIN, |
||||
| 281 | 26915263 |
CA |
69 | |
Colitis ulcerative, Harvey-Bradshaw index increased, Diarrhoea, Pouchitis, Drug specific antibody present, Product availability issue, Inappropriate schedule of product administration, Off label use, Therapy interrupted, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 282 | 26915336 |
US |
35 | 2 |
Seizure, Road traffic accident, Product use issue, Inappropriate schedule of product administration, Therapy interrupted, |
||||
ESLICARBAZEPINE ACETATE, |
||||
| 283 | 26915339 |
CA |
78 | |
Colitis ulcerative, Frequent bowel movements, Off label use, Inappropriate schedule of product administration, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 284 | 26915402 |
US |
1 | |
Blood pressure increased, Inappropriate schedule of product administration, |
||||
TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, HYDROMORPHONE HYDROCHLORIDE, FUROSEMIDE, ALLOPURINOL, ERGOCALCIFEROL, COLCHICINE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, SILDENAFIL CITRATE, MAGNESIUM CITRATE, MAJOR MAGNESIUM CITRATE ORAL SOLUTION - LEMON, BE HEALTH MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, CVS MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, EQUATE MAGNESIUM CITRATE ORAL SOLUTION - LEMON, FRESKARO MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, MAGNESIUM CITRATE ORAL SOLUTION, EPIC MEDICAL MAGNESIUM CITRATE ORAL SOLUTION - LEMON, CVS MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, BE HEALTH MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, CVS MAGNESIUM CITRATE ORAL SOLUTION - LEMON, EQUATE MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, FRESKARO MAGNESIUM CITRATE ORAL SOLUTION - LEMON, LEADER MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, LEADER MAGNESIUM CITRATE ORAL SOLUTION - LEMON, BE HEALTH MAGNESIUM CITRATE ORAL SOLUTION - LEMON, EQUATE MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, FRESKARO MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, LEADER MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, HARRIS TEETER MAGNESIUM CITRATE ORAL SOLUTION - LEMON, |
||||
| 285 | 26915453 |
US |
53 | 1 |
Liver function test increased, Inappropriate schedule of product administration, |
||||
GUSELKUMAB, GUSELKUMAB, |
||||
| 286 | 26915456 |
US |
70 | |
Therapy interrupted, Inappropriate schedule of product administration, |
||||
MITOMYCIN, MITOMYCIN, MITOMYCIN, |
||||
| 287 | 26915702 |
US |
51 | 1 |
Inappropriate schedule of product administration, Psoriasis, Inappropriate schedule of product administration, |
||||
BIMEKIZUMAB, |
||||
| 288 | 26915747 |
EU |
1 | |
Gastric bypass, Inappropriate schedule of product administration, Wrong technique in product usage process, Incorrect dose administered, |
||||
CARBIDOPA AND LEVODOPA, CARBIDOPA AND LEVODOPA, |
||||
| 289 | 26915870 |
US |
15 | 2 |
Eosinophilic oesophagitis, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 290 | 26915934 |
CA |
37 | |
Haematochezia, Defaecation urgency, Contusion, Hypoaesthesia, Influenza, Illness, Inappropriate schedule of product administration, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, PREDNISONE, |
||||
| 291 | 26916300 |
US |
2 | |
Eczema, Erythema, Pruritus, Inflammation, Therapeutic response decreased, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 292 | 26916353 |
US |
88 | 2 |
Electrocardiogram QT prolonged, Ventricular tachycardia, Drug interaction, Electrocardiogram T wave inversion, Ventricular extrasystoles, Inappropriate schedule of product administration, |
||||
SOTALOL HYDROCHLORIDE, APIXABAN, LISINOPRIL, PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, DOXYCYCLINE, DOXYCYCLINE HYCLATE, DOXYCYCLINE, DOXYCYCLINE HYCLATE, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, |
||||
| 293 | 26916419 |
US |
||
Glomerular filtration rate decreased, Inappropriate schedule of product administration, |
||||
MITOMYCIN, |
||||
| 294 | 26916515 |
41 | 2 | |
Pruritus, Petechiae, Urticaria, Rash pruritic, Inappropriate schedule of product administration, |
||||
ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, PROGESTERONE, PROGESTERONE, IODINE, |
||||
| 295 | 26916565 |
CA |
40 | 2 |
Nausea, Migraine, Hyperhidrosis, Abdominal pain upper, Abdominal pain, Inappropriate schedule of product administration, |
||||
HYDROXYCHLOROQUINE, LEVOTHYROXINE SODIUM, PROPRANOLOL HYDROCHLORIDE, NORETHINDRONE, PROCHLORPERAZINE, |
||||
| 296 | 26916591 |
US |
2 | |
Dizziness, Inappropriate schedule of product administration, |
||||
DUPILUMAB, ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, LOSARTAN POTASSIUM, LOSARTAN, ZOLPIDEM TARTRATE, |
||||
| 297 | 26916604 |
US |
2 | |
Inappropriate schedule of product administration, Product dispensing issue, |
||||
INSULIN GLARGINE, |
||||
| 298 | 26916711 |
US |
77 | |
Urinary tract discomfort, Inappropriate schedule of product administration, |
||||
MITOMYCIN, |
||||
| 299 | 26916919 |
US |
34 | 2 |
COVID-19, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 300 | 26916920 |
US |
3 | 1 |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30